Furthermore, liraglutide has been demonstrated to decrease hepatic inflammation and injury in advanced lean NASH [45], while Yu et al. provided evidence that liraglutide ameliorates NASH by inhibiting NOD-, LRR- and pyrin domain-containing protein (NLRP3) inflammasome and pyroptosis activation via mitophagy [46]. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.